The last draft guidance on using clinical outcomes assessments (COA) as endpoints in patient-focused drug development (PFDD) should use terminology more consistently, align more closely to other PFDD ...
In new guidance on patent subject matter eligibility, the USPTO has responded to six themes brought up in feedback on last year’s interim guidance. IP practitioners say new examples provided with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results